NCT01104259

Phase I Study of ABT-888 (veliparib) in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer

Study identifier: NCT01104259
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbott)

Eligibility:

• Patients with recurrent and/or metastatic triple negative breast cancer or BRCA1 or BRCA2 mutation and recurrent and/or metastatic breast cancer
• Subjects must have measurable disease, defined as at least one lesion that can be measured in at least one dimension; this includes measurable (bi-dimensional) chest wall disease and/or cutaneous metastatic lesions at least 10 mm

Type of study:

Phase I study

Treatment:

Patients receive oral ABT-888 twice daily on days 1-14 (days 0-13 of course 1 only). Patients also receive cisplatin IV and vinorelbine IV on days 1 and 8. Treatment repeats every 21 days for 6- 10 courses in the absence of disease progression or unacceptable toxicity. Treatment with ABT-888 alone may continue in the absence of disease progression or unacceptable toxicity.

Study site:

Washington

Fred Hutchinson Cancer Research Center/University of Washington Cancer
Consortium      
Seattle, Washington, 98109
Contact: Seattle Cancer Care Alliance  800-804-8824       
Principal Investigator: Eve Th Rodler

Web design by Rareheron Web Design